The combination of ICI with chemotherapy and subsequent ICI maintenance therapy may provide enhanced therapeutic efficacy for patients with ES-SCLC, potentially due to the existence of ROS1 fusions alongside TP53 and TERT mutations. This evidence concerns the gene ROS1 and small cell lung carcinoma.